1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Graphical abstract

          Abstract

          Local production of pharmaceuticals plays a vital role in maintaining resilience of national healthcare systems, especially when it comes to facilitating access to needed medicines and decreasing exposure to imports and international supply chains. Pharma is a research-intensive industry and the systemic lack of governance and support to R&D activities in this sector, among other host of related issues such as unsupportive regulatory regimes and human resources capacity limitations, is one of the major impediments to the diversifying of locally produced pharmaceuticals portfolio. In this review, an overview of the current pharmaceutical production system in Saudi Arabia, its major challenges, and proposed remedies to address them will be highlighted.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: not found
          • Article: not found

          Key factors in the rising cost of new drug discovery and development.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The Dutch health care performance report: seven years of health care performance assessment in the Netherlands

            In 2006, the first edition of a monitoring tool for the performance of the Dutch health care system was released: the Dutch Health Care Performance Report (DHCPR). The Netherlands was among the first countries in the world developing such a comprehensive tool for reporting performance on quality, access, and affordability of health care. The tool contains 125 performance indicators; the choice for specific indicators resulted from a dialogue between researchers and policy makers. In the ‘policy cycle’, the DHCPR can rationally be placed between evaluation (accountability) and agenda-setting (for strategic decision making). In this paper, we reflect on important lessons learned after seven years of health care system performance assessment. These lessons entail the importance of a good conceptual framework for health system performance assessment, the importance of repeated measurement, the strength of combining multiple perspectives (e.g., patient, professional, objective, subjective) on the same issue, the importance of a central role for the patients’ perspective in performance assessment, how to deal with the absence of data in relevant domains, the value of international benchmarking and the continuous exchange between researchers and policy makers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies

              Coronavirus disease 2019 (COVID-19) arising from Wuhan, China, is currently outbreaking worldwide. The World Health Organization (WHO) has declared COVID-19 to be a global pandemic. COVID-19 could cause a wide range of symptoms ranging from self-limiting fever, sore throat, and cough to more severe symptoms that could lead to acute respiratory distress syndrome. As a result of the lockdown and increased demand, drug shortages could become a growing global issue. This article aims to shed light on the potential impact of drug shortages as a result of this pandemic on patient outcomes and the role of pharmacists and pharmacy policymakers in alleviating this emerging problem.
                Bookmark

                Author and article information

                Contributors
                Journal
                Saudi Pharm J
                Saudi Pharm J
                Saudi Pharmaceutical Journal : SPJ
                Elsevier
                1319-0164
                2213-7475
                20 December 2021
                January 2022
                20 December 2021
                : 30
                : 1
                : 28-38
                Affiliations
                [a ]National Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia
                [b ]Drug Dimension Company, Riyadh, Saudi Arabia
                [c ]Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
                [d ]Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia
                [e ]College of Pharmacy, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
                [f ]Inpatient Department, Pharmaceutical Services Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
                [g ]Pharmaceutics Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
                [h ]Saudi Food and Drug Authority, Drug Sector, Riyadh, Saudi Arabia
                [i ]Nanobiotechnology Unit, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
                [j ]Five Dimensions for Consultation Company, Riyadh, Saudi Arabia
                Author notes
                Article
                S1319-0164(21)00249-8
                10.1016/j.jsps.2021.12.002
                8802089
                35145343
                2fa5ba2d-5c82-4032-a528-0261d86ca4c9
                © 2021 The Author(s)

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 31 October 2021
                : 15 December 2021
                Categories
                Review

                pharmaceutical production system,pharmaceutical innovation,pharmaceutical market,research and development (r&d),pharmaceuticals manufacturing in saudi arabia

                Comments

                Comment on this article